What is Envisagenics?
Envisagenics is a pioneering biotechnology enterprise dedicated to the development of novel RNA splicing therapeutics. By integrating artificial intelligence with deep biological insights, the company addresses complex genetic diseases that have historically remained difficult to treat. Its core platform, SpliceCore, allows for the rapid identification of therapeutic targets, effectively shortening the drug discovery lifecycle. As the industry pivots toward precision medicine, Envisagenics occupies a critical niche, providing the computational infrastructure necessary to decode the transcriptome and unlock new pathways for pharmaceutical innovation.
How much funding has Envisagenics raised?
Envisagenics has raised a total of $5.4M across 5 funding rounds:
Angel/Seed
$100K
Angel/Seed
$2.5M
Angel/Seed
$2.4M
Debt
$150K
Debt
$284K
Angel/Seed (2015): $100K with participation from Accelerate Long Island
Angel/Seed (2017): $2.5M led by Dynamk Capital
Angel/Seed (2017): $2.4M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Debt (2021): $284K backed by PPP
Key Investors in Envisagenics
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm that specializes in investing in life science industrials, focusing on tools, technologies, and services essential for the discovery, development, and production of life-saving therapies.
Accelerate Long Island
Accelerate Long Island is a collaborative initiative that connects research institutions, academic entities, and the business community to foster the commercialization of research and develop an entrepreneurial ecosystem.
PPP
Public-Private Partnership
What's next for Envisagenics?
With the current capital infusion, Envisagenics is well-positioned to accelerate its pipeline development and expand its strategic partnerships within the pharmaceutical industry. The focus will likely shift toward clinical validation of its lead candidates and the further refinement of its AI-driven discovery engine. By maintaining a disciplined approach to capital deployment, the company aims to solidify its market position, potentially attracting further institutional investment as it moves closer to commercializing its therapeutic assets. The roadmap ahead involves scaling operational capacity to meet the demands of a rapidly evolving biotech landscape, where data-centric approaches are increasingly becoming the standard for successful drug development.
See full Envisagenics company page
